The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomised, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly, CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomised, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2)
Inhibitors of these enzymes can help regulate blood glucose levels in individuals consuming carbohydraterich foods (Poovitha & Parani, 2016)
Methotrexate, a commonly used DMARD, restores methylation levels in RA patients to those of healthy controls after treatment, with a trend towards increased DNMT1 expression [147]
It is the primary substrate for the body's antioxidant defense network directly quenching reactive oxygen species that damage DNA, proteins, and cellular membranes
Published skin studies typically use 12-week evaluation windows
